179 filings
Page 2 of 9
8-K
xvqxq2 4fxb5
7 Nov 22
Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties
4:16pm
8-K
0g4dop
4 Nov 22
Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update
4:39pm
8-K
i95ajx6 wpy
14 Oct 22
Regulation FD Disclosure
11:32am
8-K
y8r6k lxeq
12 Aug 22
Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update
7:51am
8-K
b2xjslvba1gbc1un0hpi
17 Jun 22
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
wyee9
10 Jun 22
Amendments to Articles of Incorporation or Bylaws
4:15pm
8-K
cyirj
19 May 22
Regulation FD Disclosure
7:43am
8-K
wbnn0anu1cj3r5hcb
13 May 22
Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update
8:14am
8-K
96za grb08cd5x3
28 Apr 22
Other Events
7:16am
8-K
zmza fse2ax0nd
29 Mar 22
Regulation FD Disclosure
8:25am
8-K
vq7i fq6og3
24 Mar 22
Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended 2021 and Provides Corporate Update
8:17am
8-K
zdo0ibsw kp89
31 Jan 22
Regulation FD Disclosure
9:53am
8-K
lwk8zni
31 Jan 22
Ocuphire Presenting New Data and Updates on APX3330 and Nyxol® Clinical Programs at Virtual Investor R&D Day
6:16am
8-K
1zdm3d vpfrgf051hho
5 Jan 22
Completed Enrollment of Nyxol® LYNX-1 Phase 3 NVD Trial
7:05am
8-K
mjzzaz 02pnvwty3n
15 Nov 21
Ocuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update
12:00am
8-K
cgqhr3fz 6gdn
12 Aug 21
Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update
7:31am
8-K
w36f46t3rejsu
30 Jun 21
Regulation FD Disclosure
9:17am
8-K
2owy7qgjl mx2390fqop
23 Jun 21
Entry into a Material Definitive Agreement
4:15pm
8-K
zvwts m2esmn4zn8vkv
8 Jun 21
Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market
4:32pm
8-K/A
tuvhve7v yk
7 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm